Artículos por temáticas

Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence

Freiherr J, Hallschmid M, Frey WH 2nd, Brünner YF, Chapman CD, Hölscher C, Craft S, De Felice FG, Benedict C.

CNS Drugs. 2013 Jul;27(7):505-14. doi: 10.1007/s40263-013-0076-8.

Self-regulated music stimulation for persons with Alzheimer's disease: impact assessment and social validation

Lancioni GE, Singh NN, O'Reilly MF, Green VA, Ferlisi G, Ferrarese G, Zullo V, Perilli V, Cassano G, Cordiano N, Pinto K, Zonno N.

Dev Neurorehabil. 2013;16(1):17-26. doi: 10.3109/17518423.2012.707693. Epub 2012 Oct 3.

Impact of genetic risk assessment on nutrition-related lifestyle behaviours

Vernarelli JA.

Proc Nutr Soc. 2013 Feb;72(1):153-9. doi: 10.1017/S0029665112002741. Epub 2012 Oct 25.

Statins in the prevention of dementia and Alzheimer's disease: a meta-analysis of observational studies and an assessment of confounding

Wong WB, Lin VW, Boudreau D, Devine EB.

Pharmacoepidemiol Drug Saf. 2013 Apr;22(4):345-58. doi: 10.1002/pds.3381. Epub 2012 Dec 6.

Silicon-rich mineral water as a non-invasive test of the 'aluminum hypothesis' in Alzheimer's disease

Davenward S, Bentham P, Wright J, Crome P, Job D, Polwart A, Exley C.

J Alzheimers Dis. 2013;33(2):423-30. doi: 10.3233/JAD-2012-121231.

Evaluation of an 8-item Severe Impairment Battery (SIB-8) vs. the full SIB in moderate to severe Alzheimer's disease patients participating in a donepezil study

Schmitt FA, Saxton J, Ferris SH, Mackell J, Sun Y.

Int J Clin Pract. 2013 Oct;67(10):1050-6. doi: 10.1111/ijcp.12188.

Effects of memantine on clinical ratings, fluorodeoxyglucose positron emission tomography measurements, and cerebrospinal fluid assays in patients with moderate to severe Alzheimer dementia: a 24-week, randomized, clinical trial

Wang T, Huang Q, Reiman EM, Chen K, Li X, Li G, Lin Z, Li C, Xiao S.

J Clin Psychopharmacol. 2013 Oct;33(5):636-42. doi: 10.1097/JCP.0b013e31829a876a.

A 24-week, randomized, controlled trial of rivastigmine patch 13.3 mg/24 h versus 4.6 mg/24 h in severe Alzheimer's dementia

Farlow MR, Grossberg GT, Sadowsky CH, Meng X, Somogyi M.

CNS Neurosci Ther. 2013 Oct;19(10):745-52. doi: 10.1111/cns.12158. Epub 2013 Aug 7.

Immunological aspects and anti-amyloid strategy for Alzheimer's dementia

Liščić RM.

Arh Hig Rada Toksikol. 2013 Dec;64(4):603-8. doi: 10.2478/10004-1254-64-2013-2414.

Motor effects of REAC in advanced Alzheimer's disease: results from a pilot trial

Olazarán J, González B, López-Álvarez J, Castagna A, Osa-Ruiz E, Herrero-Cano V, Agüera-Ortiz L, Rinaldi S, Martínez-Martín P.

J Alzheimers Dis. 2013;36(2):297-302. doi: 10.3233/JAD-130077.

β-Arrestins as potential therapeutic targets for Alzheimer's disease

Jiang T, Yu JT, Tan MS, Zhu XC, Tan L.

Mol Neurobiol. 2013 Dec;48(3):812-8. doi: 10.1007/s12035-013-8469-8. Epub 2013 May 16.

[Aβ immunotherapy for Alzheimer's disease]

Sakai K, Yamada M.

Brain Nerve. 2013 Apr;65(4):461-8.

A randomized controlled Alzheimer's disease prevention trial's evolution into an exposure trial: the PREADViSE Trial

Kryscio RJ, Abner EL, Schmitt FA, Goodman PJ, Mendiondo M, Caban-Holt A, Dennis BC, Mathews M, Klein EA, Crowley JJ; SELECT Investigators.

J Nutr Health Aging. 2013 Jan;17(1):72-5. doi: 10.1007/s12603-012-0083-3.

From the multifactorial nature of Alzheimer`s disease to multitarget therapy: the contribution of the translational approach

Calzà L, Baldassarro VA, Giuliani A, Lorenzini L, Fernandez M, Mangano C, Sivilia S, Alessandri M, Gusciglio M, Torricella R, Giardino L.

Curr Top Med Chem. 2013;13(15):1843-52. doi: 10.2174/15680266113139990140.

Lessons learnt from glycogen synthase kinase 3 inhibitors development for Alzheimer's disease

Martinez A, Perez DI, Gil C.

Curr Top Med Chem. 2013;13(15):1808-19. doi: 10.2174/15680266113139990138.